A Phase 4 Study of Zytiga in Poor-risk mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients Who Was Failed the First-line CAB (Combined Androgen Blockade) Therapy
Phase of Trial: Phase IV
Latest Information Update: 06 Mar 2018
At a glance
- Drugs Abiraterone acetate (Primary) ; Prednisolone
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Janssen Pharmaceutical KK
- 28 Feb 2018 Status changed from active, no longer recruiting to completed.
- 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
- 14 Jul 2017 Planned End Date changed from 31 Mar 2017 to 31 Dec 2018.